Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATARTIC trial
2021-002325-18Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and capecitabine in rectal cancer, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathologic complete response. Started Jul 2021; status: active.
02
Drugs
temozolomidecapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2021-002325-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002325-18.